uniQure N.V. (QURE): Operating Income
-$185.35M
Year ended 2025-12-31
-$191.74M
Trailing 12 months to 2026-03-31
| Period ended | Operating Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$185.35M | n/m | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | -$184.29M | n/m | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | -$282.87M | n/m | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | -$143.16M | n/m | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $310.62M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$125.43M | n/m | 2023-02-27, From 2020-01-01 |
| 2019-12-31 | -$121.14M | n/m | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | -$88.23M | n/m | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | -$71.34M | n/m | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | -$71.95M | n/m | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | -$71.15M | n/m | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | -$53.68M | n/a | 2017-03-15, From 2014-01-01 |
Operating Income at similar companies
| Company | Year ended | Operating Income | Change YoY |
|---|---|---|---|
| uniQure N.V. (QURE) | 2025-12-31 | -$185.35M | n/m |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | -$38.60M | n/m |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | -$38.16M | n/m |
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | -$84.42M | n/m |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | -$470.0K | n/m |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | -$7.54M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | -$125.70M | n/m |
| Evommune, Inc. (EVMN) | 2025-12-31 | -$81.07M | n/m |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $3.37M | n/m |
Compare QURE, IRD, ABUS, PYXS side by side · Screen every company in Pharmaceutical Preparations ↗